Biological activity of GLP-1-analogues with N-terminal modifications

Regulatory Peptides

Volumn 79, Issue 2-3, 1999, Pages 93-102

  Siegel, Erhard G ^a   Gallwitz, Baptist ^a   Scharf, Gritie ^a   Mentlein, Rolf ^b   Morys Wortmann, Corinna ^c   Fölsch, Ulrich R ^a   Schrezenmeir, Jürgen ^d   Drescher, Karsten ^d   Schmidt, Wolfgang E ^a  

^a Laboratory of Molecular Gastroenterology and Hepatology   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^d Kiel and Lungen Clinic Grosshansdorf   (Germany)

Author keywords

Dipeptidyl peptidase IV; GLP 1 analogues; Glucagon like peptide 1; Isolated rat islets; RINm5F cells

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GLUCAGON LIKE PEPTIDE 1; PEPTIDE DERIVATIVE;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG RECEPTOR BINDING; FEMALE; GLUCOSE BLOOD LEVEL; INSULIN BLOOD LEVEL; KIDNEY; NONHUMAN; PANCREAS ISLET; PRIORITY JOURNAL; RAT; RECEPTOR AFFINITY; SIGNAL TRANSDUCTION; STRUCTURE ACTIVITY RELATION; SUBCUTANEOUS DRUG ADMINISTRATION; SWINE;

EID: 0032782401     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-0115(98)00155-4     Document Type: Article

References (37)

1. Patzelt C, Schiltz E Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences. Proc Natl Acad Sci USA. 81:1984;5007-5011.
2. Mojsov S, Heinrich G, Wilson JB, Ravazzola M, Orci L, Habener JF Preproglucagon gene expression diversifies at the level of posttranslational processing. J Biol Chem. 261:1986;11880-11889.
3. Orskov C, Holst JJ, Seier Poulsen S, Kirkegaard P Pancreatic and intestinal processing of proglucagon in man. Diabetologia. 30:1986;874-881.
4. Orskov C Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia. 35:1992;701-711.
5. Schmidt WE, Siegel EG, Creutzfeldt W Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia. 28:1985;704-707.
6. Kreymann B, Williams G, Ghattei MA, Bloom SR Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet. ii:1987;1300-1304.
7. Gutniak M, Orskov C, Holst JJ, Ahren B, Efendic S Antidiabetic effect of glucagon-like peptide 1 [7-36 amide] in normal subjects and patients with diabetes. N Engl J Med. 326:1992;1316-1322.
8. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W Preserved incretin activity of glucagon-like peptide 1 (GLP-1) [7-36 amide] but not of synthetic human gastric inhibitory polypeptide (GIP) in patients with type 2 diabetes mellitus. J Clin Invest. 91:1993;301-307.
9. Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide-1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia. 36:1993;741-744.
10. Nauck MA, Holst JJ, Willms B, Schmiegel W Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes. Exp Clin Endocrinol Diabetes. 105:1997;187-195.
11. Ritzel R, Holst JJ, Orskov C, Nauck MA Pharmacokinetic, insulinotropic, and glucagonostatic properties of GLP-1 [7-36 amide] after subcutaneous injection in healthy volunteers. Dose-response relationships. Diabetologia. 38:1995;720-725.
12. Mentlein R, Gallwitz B, Schmidt WE Dipeptidyl peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 214:1993;829-835.
13. 2-terminus in type 2 diabetic patients and in healthy subjects. Diabetes. 44:1995;1126-1131.
14. Kieffer TJ, McIntosh CHS, Pederson RA Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 136:1995;3585-3596.
15. Adelhorst K, Hedegaard BB, Knudsen LB, Kirk O Structure-activity studies of glucagon-like peptide-1. J Biol Chem. 269:1994;6275-6278.
16. Gallwitz B, Witt M, Paetzold G, Morys-Wortmann C, Zimmermann B, Eckart K, Fölsch UR, Schmidt WE Structure/activity characterization of glucagon-like peptide-1. Eur J Biochem. 225:1994;1151-1156.
17. Gallwitz B, Witt M, Paetzold G, Morys-Wortmann C, Fölsch UR, Schmidt WE GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1. Regul Pept. 63:1996;17-22.
18. α-fluorenylmethoxy carbonylamino acid pentafluorophenyl esters. Chem Commun 1985:165-166.
19. Dryland A, Sheppard RC Peptide synthesis VIII. A system for solid phase synthesis under low pressure continuous flow conditions. Perkin Trans. 1:1986;125-137.
20. Schmidt WE, Kratzin H, Eckart K, Drews D, Mundkowski D, Clemens A, Katsoulis S, Schäfer H, Gallwitz B, Creutzfeld W Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptide. Proc Natl Acad Sci USA. 88:1991;11435-11439.
21. David R, Macnair C, Kenny AJ Proteins of the kidney microvillar membrane. The amphipatic form of dipeptidyl peptidase IV. Biochem J. 179:1979;379-395.
22. Mentlein R, Lucius R Methods for the investigation of neuropeptide catabolism and stability in vitro. Brain Res Protocols. 1:1997;237-246.
23. Praz GA, Halban PA, Wolheim CB, Blondel B, Strauss AJ, Renold AE Regulation of immunoreactive insulin release from a rat cell line (RINm5F). Biochem J. 210:1983;345-352.
24. Burton K A study of the conditions and mechanisms of diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J. 62:1956;315-323.
25. Gallwitz B, Witt M, Fölsch UR, Creutzfeld W, Schmidt WE Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells. J Mol Endocrinol. 10:1993;259-268.
26. 125I-labelled human growth hormone of high specific radioactivity. Nature. 194:1962;495-496.
27. Trinder P Determination of glucose in blood using 4-amino phenazone as oxygen acceptor. J Clin Pathol. 22:1969;246.
28. Creutzfeldt W, Ebert R. The enteroinsular axis. In: Go VWL, DiMagno EP, Gardner JD, Lebenthal E, Reber HA, Scheele G, editors. The pancreas: biology pathobiology and diseases. New York: Raven Press, 1993:769-788.
29. Markussen J, Andersen AS, Vad K Synthesis of the soluble, long-acting insulin NN304. Diabetes. 45:1996;219A.
30. Mentlein R, Dahms P, Grandt D, Krüger R Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept. 49:1993;133-144.
31. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CHS, Demuth HU Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes. 47:1998;1253-1258.
32. Evans BE, Bock MG, Rittle KE, DiPrado RM, Whitter WL, Veber DF, Anderson PS, Freidinger RM Design of potent orally effective nonpeptidal antagonists for the peptide hormone cholecystokinin. Proc Natl Acad Sci USA. 83:1986;4918-4922.
33. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Peteher TJ, Pless J SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31:1982;133-140.
34. Gallwitz B, Witt M, Paetzold G, Morys-Wortmann C, Fölsch UR, Schmidt WE Binding characteristics of N-terminal GIP/GLP-1 hybrid peptides. Endocrinol Metabol. 2:1995;39-46.
35. Hupe-Sodmann K, McGregor GP, Bridenbaugh R, Göke R, Göke B, Thole H, Zimmermann B, Voigt K Characterization of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36)amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 58:1995;149-156.
36. Hupe-Sodmann K, Göke R, Göke B, Thole HH, Zimmermann B, Voigt K, McGregor GP Endoproteolysis of glucagon-like peptide (GLP)-1(7-36)amide by ectopeptidases in RINm5F cells. Peptides. 18:1997;625-632.
37. Deacon CF, Knudsen LB, Madsen K, Wiberg FC, Jacobsen O, Holst JJ Dipeptidyl-peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity. Diabetologia. 41:1998;271-278.